-
Aurobindo to acquire dermatology and oral solids businesses from Sandoz
financialexpress
September 07, 2018
The acquisition is in line with Aurobindo’s strategy to grow and diversify our business in the US
-
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
worldpharmanews
September 07, 2018
Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billi
-
Aurobindo launches $1.6 billion bid to buy Novartis generics unit
biospectrumasia
May 08, 2018
Novartis is considering a sale of its dermatology generics drugs business under the Sandoz brand
-
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
fiercepharma
May 08, 2018
As Novartis tries to shed some of its Sandoz offerings in the U.S. under intense pricing pressure, the drugmaker may have found a buyer for a generic dermatology business. India's Aurobindo has submitted a $1.6 billion offer for the unit, according to Liv
-
FDA finds major manufacturing issues at key Aurobindo facility
pharmafile
March 06, 2018
Indian pharmaceutical company Aurobindo was screened by the USFDA and the review identified nine major problems with its unit 4 in Hyderabad, India
-
Aurobindo Pharma gets US FDA nod for heartburn drug
expressbpd
October 18, 2017
Aurobindo Pharma has received final approval from the US health regulator to manufacture Esomeprazole Magnesium delayed-release capsules, used in treatment of frequent heartburn, in the US market.
-
Aurobindo to expand into EU, US over next three to four years
financialexpress
July 05, 2017
The company looks to launch various new products in the US market
-
Aurobindo to expand into EU, US over next three to four years
expressbpd
July 05, 2017
The company looks to launch various new products in the US market